BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases ...
Sjögren's syndrome may lead to dental caries, periodontal disease, denture intolerance, candidosis and dysphagia. This study evaluated the use of a hydrogel polymer buccal insert as a controlled ...
The company's experimental dry-eye treatment produced some disappointing clinical trial results. Ocular Therapeutix's only revenue-generating product, Dextenza, isn't making ends meet yet. Investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback